The Question
A 62-year-old man with a 50 pack-year smoking history, who quit 5 years ago, presents with progressive cough. Chest CT reveals a 3.1 cm spiculated peripheral right upper lobe mass. FDG-PET shows intense uptake in the mass (SUV 10) but no FDG-avid mediastinal or hilar lymph nodes. Pulmonary function testing shows FEV1 48% predicted and DLCO 50% predicted; he has coronary artery disease but preserved left ventricular function. Thoracic surgery considers him borderline for lobectomy because of reduced pulmonary reserve. Which of the following is the most appropriate next step in management?
See the answer and explanation below:
Post-Call Recovery Reads
Finished your notes? Time to swap the pager for a crown. Kingdoms of Silent Sorrows is the ultimate 'brain-break', a high-stakes fantasy featuring a Fae princess, a Vampire king, and an enemies-to-lovers arc that will actually make you forget about your rounding list. No p-values, just fated mates and forbidden magic.
View on AmazonThe Correct Answer
A
Explanation
High-Yield Pearl: For a solitary PET-avid peripheral pulmonary mass, obtain a tissue diagnosis with CT-guided core-needle biopsy when feasible to establish histology and enable molecular testing before definitive therapy.
Detailed Reasoning: CT-guided percutaneous core-needle biopsy has high diagnostic yield for peripheral lung lesions and typically provides sufficient tissue for histologic classification and molecular testing (EGFR, ALK, ROS1, BRAF, PD-L1) that guide modern NSCLC therapy, consistent with NCCN recommendations. Endobronchial ultrasound is most useful for mediastinal nodal staging when nodes are PET-avid or enlarged; it is less sensitive for sampling a peripheral parenchymal mass and is unnecessary here given nonavid mediastinum. Proceeding directly to lobectomy without a tissue diagnosis can be reasonable in select patients who are excellent surgical candidates with very high pretest probability, but this patient has borderline pulmonary reserve (FEV1 and DLCO ~48–50% predicted), making nonoperative options and careful planning important; thus tissue diagnosis to guide less invasive therapy is preferred. SBRT is an established definitive option for medically inoperable patients but guidelines advise obtaining histologic confirmation whenever feasible because treatment and systemic therapy decisions depend on tumor type and biomarkers. Empiric chemotherapy without biopsy is inappropriate because systemic regimens and targeted agents depend on histology and molecular results and because misclassification could lead to ineffective or harmful therapy.
See you tomorrow morning!